TIDMAVO

RNS Number : 8320B

Advanced Oncotherapy PLC

06 April 2017

6 April 2017

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Total Voting Rights

Further to the announcement of 7 November 2016, Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that due to a clerical error, 24,505 new ordinary shares of 25 pence each in the Company ("Ordinary Shares") were not issued and allotted of the 266,668 new Ordinary Shares to be issued as stated in the aforementioned announcement.

Therefore, the Company's issued share capital comprises 72,647,193 Ordinary Shares, with voting rights. The Company does not hold any Ordinary Shares in treasury. This figure of 72,647,193 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 
  Advanced Oncotherapy Plc                                       www.avoplc.com 
  Dr. Michael Sinclair, Executive                         Tel: +44 20 3617 8728 
   Chairman 
  Nicolas Serandour, CEO 
 
  Stockdale Securities (Nomad & 
   Joint Broker) 
  Antonio Bossi / David Coaten                            Tel: +44 20 7601 6100 
 
  Stifel Nicolaus Europe (Joint 
   Broker) 
  Jonathan Senior / Ben Maddison                          Tel: +44 20 7710 7600 
 
  Walbrook PR (Financial PR & IR)   Tel: +44 20 7933 8780 or avo@walbrookpr.com 
  Paul McManus / Anna Dunphy                   Mob: +44 7980 541 893 / Mob: +44 
                                                                   7876 741 001

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVREADLKEEXXEFF

(END) Dow Jones Newswires

April 06, 2017 09:07 ET (13:07 GMT)

Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Advanced Oncotherapy Charts.
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Advanced Oncotherapy Charts.